Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 13/20 | 0.57 |
| ▸ | VHL | P40337 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MERTK | Q12866 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30908029 | 1.00 | AR (0.57) | ARVHLBRD4RAF1BRAF | |
| SCHEMBL28650197 | 0.99 | AR (0.58) | ARVHLBRD4RAF1BRAF | |
| SCHEMBL25942687 | 0.92 | AR (0.60) | ARVHLRAF1BRAFNPC1 | |
| SCHEMBL30219486 | 0.92 | AR (0.61) | ARVHLBRD4RAF1BRAF | |
| SCHEMBL26464151 | 0.92 | AR (0.61) | ARVHLBRD4RAF1BRAF | |
| SCHEMBL23846235 | 0.90 | AR (0.61) | ARVHLRAF1BRAFNPC1 | |
| SCHEMBL22263332 | 0.89 | AR (0.60) | ARVHLRAF1BRAFNPC1 | |
| SCHEMBL28667525 | 0.88 | AR (0.54) | ARVHLRAF1BRAFNPC1 | |
| Hydrochloric Acid SCHEMBL30938120 | 0.88 | AR (0.59) | ARVHLNPC1RAB9ALMNA | |
| Hydrochloric Acid SCHEMBL22263225 | 0.88 | AR (0.59) | ARVHLNPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002360-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2024-01-04 | — | — | US | disclosed |
| US-11787778-B2 | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | MONTELINO THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787778-B2 | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | AR, ADRM1, PSMA3 | AR 1/4885VHL 525/4885BRD4 296/4885 |
| US-20240002360-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | AR 1/4885VHL 491/4885BRD4 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.